Author: Dr. Zandra Klippel, Global Product Head, Multiple Myeloma, Sanofi
At the ASCO 2024 conference, Dr. Zandra Klippel the Global Product Head, Multiple Myeloma, Sanofi summarizes the promising Phase 3 results from the IMROZ study. This study evaluated the combination of Sarclisa (isatuximab) with VRd (bortezomib, lenalidomide, and dexamethasone) in patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant.
Key Findings:
- Efficacy: The addition of Isatuximab to VRd significantly improved the depth of response and progression-free survival (PFS), showing a positive trend in overall survival (OS).
- Treatment Duration: The median treatment duration was notably longer in the Isa-VRd arm (53 months) compared to VRd alone (31 months), without a detriment in quality of life.
- Subgroup Consistency: Benefits were consistent across various subgroups, including different age ranges and risk profiles.
- Safety Profile: The safety profile was manageable, with no unexpected adverse events, despite the longer exposure period. The main adverse events were cytopenias and liver abnormalities, which were managed with dose adjustments and steroids.
Future Research Directions: Ongoing research aims to optimize dosing, reduce side effects, and expand the use of Isa-VRd to other myeloma populations, including those eligible for transplant. Future trials will explore different dosing schedules and delivery methods, such as subcutaneous administration of Sarclisa.
Outbound Links:
ASCO Abstract: https://meetings.asco.org/abstracts-presentations/231717
Sanofi Press Release: https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-03-20-15-00-2892607
Internal Links: